NCT04080947View on ClinicalTrials.gov

The Leukotriene Receptor Antagonist Montelukast in the Treatment of Non-alcoholic Steatohepatitis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

August 1, 2019

Primary Completion Date

August 31, 2021

Study Completion Date

March 15, 2022

Conditions
Steatohepatitis, Nonalcoholic
Interventions
DRUG

Control group

patients received matching-image placebo once daily at bedtime for 12 weeks.

DRUG

Montelukast group

patients received montelukast (10-mg chewable tablet) once daily at bedtime for 12 weeks.

Trial Locations (1)

13829

Faculty of Medicine, Shibīn al Kawm

All Listed Sponsors
lead

Sadat City University

OTHER

NCT04080947 - The Leukotriene Receptor Antagonist Montelukast in the Treatment of Non-alcoholic Steatohepatitis | Biotech Hunter | Biotech Hunter